Table 2.

Comparison of biopsy strategies on lesion and patient level.

Parameter	1 Bcx vs. Bsat		2 Bcx vs. Bsat		3 Bcx vs. Bsat		n
	n (%)	p	n (%)	p	n (%)	p	Total
RS—Lesions
Cancer missed (total)	21 (36.2)	0.003	12 (20.7)	0.018	6 (10.3)	0.07	58
Cancer missed (> ISUP I)	24 (53.3)	0.001	15 (33.3)	0.008	7 (15.6)	0.052	45
Gleason upgrade	34 (58.6)	–	22 (37.9)	–	12 (20.7)	–	58
Change in definitive treatment1	24 (41.4)	< 0.001	15 (25.9)	0.004	7 (12.1)	0.15	58
Insufficient staging2	11 (19.0)	0.028	5 (8.6)	0.3	3 (5.2)	0.56	58
RS—Patients
Cancer missed (total)	17 (37.0)	0.006	10 (21.7)	0.03	5 (10.9)	0.09	46
Cancer missed (> ISUP I)	18 (50)	0.003	12 (33.3)	0.01	5 (13.9)	0.08	36
Gleason upgrade	28 (60.9)	–	19 (41.3)	–	10 (21.7)	–	46
Change in definitive treatment1	18 (39.1)	< 0.001	12 (26.1)	0.01	5 (10.9)	0.24	46
Insufficient staging2	10 (21.7)	0.026	5 (10.9)	0.28	3 (6.5)	0.52	46
WCS—Lesions
Cancer missed (total)	35 (60.3)	< 0.001	26 (44.8)	0.002	17 (29.3)	0.007	58
Cancer missed (> ISUP I)	33 (73.3)	0.003	28 (62.2)	0.002	20 (44.4)	0.003	45
Gleason upgrade	50 (86.2)	–	45 (77.6)	–	35 (60.3)	–	58
Change in definitive treatment1	33 (56.9)	< 0.001	28 (48.3)	< 0.001	20 (34.5)	< 0.001	58
Insufficient staging2	18 (31.0)	< 0.001	16 (27.6)	0.001	12 (20.7)	0.02	58
WCS—Patients
Cancer missed (total)	28 (60.9)	< 0.001	21 (45.7)	0.002	15 (32.6)	0.008	46
Cancer missed (> ISUP I)	25 (69.4)	< 0.001	21 (58.3)	0.002	17 (47.2)	0.004	36
Gleason upgrade	41 (89.1)	–	36 (78.3)	–	28 (60.9)	–	46
Change in definitive treatment1	25 (54.3)	< 0.001	21 (45.7)	< 0.001	17 (37.0)	< 0.001	46
Insufficient staging2	15 (32.6)	< 0.001	14 (30.4)	0.002	11 (23.9)	0.01	46

B_cx, targeted biopsy core; B_sat, saturation biopsy; RS, random selection; WCS, worst case scenario.

¹Definition: Definitive treatment according to Gleason score (> 6) indicated.

²Staging for distant metastasis according to Gleason score (> 7a).